Recipharm signs manufacturing agreement with Alcon and

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 21, 2015 at 8:45 AM

Recipharm signs manufacturing agreement with Alcon and acquires facility in France, adding new niche capabilities

Recipharm AB today announces that it has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and today signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology. As part of this collaboration, Recipharm will also acquire from Alcon, Kaysersberg Pharmaceuticals, a company whose main asset is a manufacturing facility located in Kaysersberg, France which currently supplies this product range. Highlights · Long term manufacturing agreement will add annual sales in excess of EUR 36 million and EBITDA-margin well in line with the Group’s average. · Adds a new important relationship with Alcon and further strengthens the current relationship with Novartis. · 100% of the shares in Kaysersberg Pharmaceuticals will be acquired for a total consideration of EUR 18 million. · Extends Recipharm’s manufacturing services offering with the growing technology of Blow Fill Seal. · Provides potential synergy with Recipharm’s three other French facilities. · Approximately 260 people currently employed by Kaysersberg Pharmaceuticals will continue their employment under Recipharm ownership. · Closing is expected to take place on 31st December 2015. There are no material conditions to closing. Thomas Eldered, CEO Recipharm AB commented “We are looking forward to extending our relationship with Alcon and Novartis and I am very pleased that they have had the confidence in Recipharm to make this commitment of a long term manufacturing agreement and sale of Kaysersberg Pharmaceuticals. Blow Fill Seal technology is a very interesting area which we believe will grow and it therefore forms an important addition to our portfolio. The high skill levels and dedicated employees in Kaysersberg will be a welcome addition into Recipharm and we look forward to working with them to further develop and grow the business”. Financing and payment terms · The consideration of EUR 18 million will be paid in cash with 75% in 2015 and 25% in January 2016. · In addition, Recipharm will acquire working capital for approximately EUR 4.2 million. · The acquisition will be financed will already available funds. No further financing will be required. For further information please visit www.recipharm.com or contact: Thomas Eldered, Thomas.eldered@recipharm.com, +46 8 602 52 10 Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 21st December 2015, at 14:30 CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com Recipharm has retained Rambauld Legoater as legal advisors. About Kaysersberg Pharmaceuticals The Kaysersberg facility is located in Alsace, France and employs around 260 people. The facility was acquired by Alcon in 1984. Alcon is the second largest division of Novartis. The facility is dedicated to Blow Fill Seal (BFS)/Form Fill Seal technology, is well invested and fully GMP compliant with approvals from FDA, EU, ANVISA and Japan. It is 25.000 m2 with a manufacturing area of 7.000 m2 with 7 production lines and 10 packaging lines. The facility manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03 www.recipharm.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CopperWood Senior Living Revives Historic Campus

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Digital Art Sparks Future City Visions in Beijing

Beijing's Bold Digital Art Venture: A New Era in Creativity Ever felt the jittery buzz of innovation on the cutting edge? That's exactly what visitors experienced in Beijing's 'Spiritual Land: Future World of Inspiration' exhibition at the BOE Yiyun Digital Art Center. Set against the backdrop of the sprawling metropolis, this joint effort between Beijing and Linz aims to...

XREAL AURA: A New Era of Wired XR Glasses

Pioneering the XR Frontier Welcome to another day under the sun of cutting-edge tech, where XREAL's striking a chord with its new wired XR glasses—AURA. First off, don't let the tangled history of tech hype get to you. In the wild world of extended reality, we've seen plenty of flash, not enough substance. But XREAL's hitting the market with AURA, and I gotta say,...

Hershey's Sweet Results: 2026 Earnings Soar

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

DayOne's Bold Energy Moves With Sembcorp for Asia Growth

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Direxion Targets Anthropic's IPO with Bold New ETFs

Anthropic's IPO Sparks Direxion's Latest ETF Moves Alright, folks, Anthropic's public filing for an IPO isn't just turning heads—it's lighting up the trading floor! Following this buzz, Direxion grabs its chance to unleash two new ETFs designed to seize on Anthropic's rollercoaster debut. We're talking about the Direxion Daily Anthropic Bull 2X ETF (ANTO) and the...

GARDANT Expands Reach with International Partnership

GARDANT Global's Strategic Expansion Well, today we saw GARDANT Global make a move that screams ambition. They’re hooking up with International Offset Corporation (IOC) to muscle up their game in the murky waters of government procurement. Why does this matter? Because it's all about who gets the contracts, and with GARDANT’s newfound reach, they’re not just...